1. A vaccine formulation for nasal administration wherein the components are (a) a surface antigen from virus and (b) one or more vaccine antigens synergizing in adjuvant effect with (a), the antigen concentrations is in the range up to 1 mg each, preservatives and stabilizers can be added.

- 2. A vaccine formulation according to claim 1, wherein component (a) is the Hepatitis B Virus surface antigen and the component (b) is an antigen of viral nucleocapsid.
- **3.** A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigen of Hepatitis B Virus.
- **4.** A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigens of Human Papilloma-Virus.
- 5. A vaccine formulation according to claim 1 and 2, wherein component (b) is a virus-like particle containing the nucleocapsid antigens of Hepatitis C Virus.
- 6. A vaccine formulation according to claim 1, wherein component (a) is the Hepatitis B Virus surface antigen and the component (b) is a vaccine antigen of any nature or a mixture of different antigens receiving an immuno-enhancing effect from Hepatitis B surface antigen.
- **7.** A vaccine formulation according to claims 1-6, administrated as a solid, liquid or spray product.
- **8.** A vaccine formulation according to claims 1-6 for mucosal administration.
- **9.** A vaccine formulation according to claims 1-6 for use as a therapeutic vaccine.
- **10.** A vaccine formulation according to claims 1-6 for use as a preventive vaccine.

10

O9057402.O9170

<u></u> 20

30

25